And so it ends. Today, we wrap up our five-part series on German American Depositary Receipts (ADRs) trading on U.S. stock exchanges.

What a long, depressing trip it's been.

We've toured Germany's old economy, its banks and insurers, its natural-gas suppliers and chemical stirrer-uppers -- and we've found, for the most part, stagnant earnings growth and high equity prices. We've taken a microscope to German semiconductors and found a surprising dearth of profits, in contrast to the earnings strength evident in their American counterparts. Finally, yesterday, we looked at the country's health-care sector -- finding one fairly priced dialysis provider and two pharmas whose income statements could use a bit of intensive care themselves.

Now, we'll polish off the company's ADR offerings with a quick trip through the remainder of the high-tech sector. We'll look at biotech, telecom, software, and electronic gadgets. That's right, folks -- look sharp, because today's the last time (for a while, at least) that we'll be .

Getting to know this country

GPC Biotech
(Level II ADR) 1 ADR = 1 Common Share

What's in a name? The first line above tells you essentially all you need to know about GPC Biotech (NASDAQ:GPCB). First, it's a biotech -- meaning it's losing money. Second, it's on the Nasdaq, which means it's . losing money.

Sorry. Cheap shots both, I know, but in GPC's case, it's true. The company, whose name refers to the initials of its previous corporate name, "Genome Pharmaceuticals Corporation," burned through about $130 million worth of free cash flow from 2000 through 2005, and its rate of cash burn is accelerating. That situation may change soon, since the company does have one drug, satraplatin, in a phase 3 trial for the treatment of prostate cancer. Or it may not -- GPC has two other cancer-drug candidates working their way through the regulatory process, and they're burning up cash along the way.

The good news is that GPC also has a stack of cash piled up that should suffice to cover its operations for the next three years at the current burn rate. The bad news -- you never know whether a biotech is going to hit it big or just burn out.

Or, rather, I never know. The Fool's resident biotech analyst, Charly Travers, has a much better feel for these kinds of things. If you're a subscriber to Motley Fool Rule Breakers, or if you even just want to give the service a try for one free month, you can post a note on the Rule Breakers discussion boards and get quick feedback from Charly and the other Rule Breaking Fools on GPC's prospects for greatness.

Deutsche Telekom
(Level III ADR) 1 ADR = 1 Common Share

Now we turn to the big names in corporate Germany. Everyone knows Deutsche Telekom (NYSE:DT). The German telecom and information technology giant operates the T-Mobile cell phone brand, the largest telecom company in Europe.

The company that's so popular among global business travelers also looks attractively priced relative to its competitors. It sports a P/E of 8.2, yet analysts expect it to grow its earnings at 9.1% per annum over the next five years. That's nowhere near the explosive growth that analysts expect to see at next-door neighbor and Motley Fool Income Investor pick France Telecom (NYSE:FTE). But it still gives Deutsche Telekom an attractive PEG ratio of 0.9.

Combine that favorable valuation with Deutsche Telekom's generous dividend payouts (the stock yields 4.6%), and Deutsche Telekom deserves a look from globetrotting income investors looking to diversify away from an overvalued dollar.

(Level II ADR) 1 ADR = 1 Common Share

Siemens (NYSE:SI) defines the modern high-tech conglomerate. Through its various divisions, it can tell you what to do (IT consulting), build you the stuff to do it with (enterprise solutions, carrier networks, and wireless modules), and then integrate the stuff into your business (IT systems integration). In doing so, Siemens competes with rivals both small and large, near and far, from ABB next door in Switzerland to GE (NYSE:GE) right here in the United States.

Thanks to the company's U.S. ADR program, you can easily buy yourself a piece of the Siemens action, but it won't come cheap. The company's shares currently change hands for a whopping 34 times trailing earnings. That looks like a pretty steep price to pay given that analysts expect Siemens to grow its profits at only 7% per annum in the long term, and even with foreign analysts calling for 22% growth in profits next year, 34 times earnings looks a bit on the pricey side.

From a U.S. investor's perspective, I'd be much more inclined to invest with local hero GE. At 24 times trailing earnings and with 11% growth projected, this firm is no bargain, but it is cheaper, and GE's 3% dividend trumps Siemens' 1.8% to boot.

(Level II ADR) 1 ADR = 0.25 Common Share

If you're a buyer of BMWs and Hugo Boss suits -- if, in other words, you just have to overpay for quality and view a 30-odd times multiple to earnings as a mark of distinction rather than as a ridiculously large price tag, then SAP (NYSE:SAP) looks like a better bet than Siemens. The shares cost more at 36 times earnings, but you get more growth for your Euros here: 12.3% projected on Yahoo! Finance, and the 45 (yes, 45) analysts who track SAP worldwide project 20% earnings growth next year.

The software maker also sports software maker-like margins: 27% operating and 18% net, which are not too far behind rivals Microsoft (NASDAQ:MSFT) and Oracle. Its 29% return on equity looks sterling against the backdrop of a clean balance sheet holding more than $4 billion in cash. In other words, this is the creme de la creme of the German ADR universe.

In short, SAP is an excellent business -- with a price tag to match. Buy at your own risk, and pray the company never misses an earnings target.

And there you have it. Eighteen German ADRs for the taking. Not all of them are necessarily worth taking, but I hope this series has helped to highlight the few German companies that are worth taking a look at, for your future due-diligence delight.

Fool on!

For more coverage on Germany and the Olympics:

Microsoft is a Motley Fool Inside Value recommendation. For more of the market's best bargains, take Inside Value for a free 30-day trial.

Fool contributor Rich Smith does not own shares of any company named above.